No headlines found.
No press releases found.
No news found.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Anbio Biotechnology - Class A trades on the NASDAQ stock market under the symbol NNNN.
As of September 11, 2026, NNNN stock price declined to $6.34 with 268,293 million shares trading.
NNNN has a beta of 1.69, meaning it tends to be more sensitive to market movements. NNNN has a correlation of 0.03 to the broad based SPY ETF.
NNNN has a market cap of $278.27 million. This is considered a Small Cap stock.
NNNN has underperformed the market in the last year with a price return of -85.4% while the SPY ETF gained +17.4%. NNNN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.4% and -17.3%, respectively, while the SPY returned +3.9% and -0.7%, respectively.
NNNN support price is $5.87 and resistance is $7.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NNNN shares will trade within this expected range on the day.
